Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab, Balstilimab, FMD, and Vitamin C in KRAS-Mutant Metastatic Colorectal Cancer
NCT06336902Phase 1Recruiting
- Sponsor
- University of Southern California
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botensilimab and balstilimab in metastatic colorectal cancer (mCRC), sponsored by University of Southern California. Primary endpoints: Proportion of patients who adhere to the fast mimicking diet up to 30 months and Incidence of adverse events up to 30 months. Started Jan 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06336902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06336902.